

October 2018 Anthem Wisconsin Provider Newsletter

Update to AIM Specialty Health clinical appropriateness guidelines	1
Update to AIM Specialty Health radiation oncology clinical appropriateness guidelines	2
Update to AIM Specialty Health sleep disorder management clinical appropriateness guidelines	3
Anthem fights opioid addiction: Extension for Community Healthcare Outcomes and Quality Medication-Assisted Therapy	4
Health Care Reform (including Health Insurance Exchange) Updates and Notifications	5
Access patient-specific drug benefit information through EMR	5
Anthem expands specialty pharmacy prior authorization list	6
Anthem expands specialty pharmacy level of care (clinical site of care) drug list ...	6
Anthem expands specialty pharmacy clinically equivalent drug list	7
Pharmacy information available at anthem.com	7
Updated Provider Manual posted to anthem.com	7
Anthem launches additional changes to anthem.com in October	8
Availity: Anthem's EDI Gateway is now through Availity	9
Availity EDI Gateway Webinars Scheduled	10
Explore new enhancements to the Availity Education and Reference Center	11
Special Investigations Unit (SUI) Updates: FDA Warnings	11
HEDIS® 2018: Provider Incentive Winners Announced!	12
Are you looking for innovative ways to improve your patients' experiences and earn CME credits?	13
Update to Durable Medical Equipment - effective October 14, 2018	14
Clinical practice and preventive health guidelines	15
Integrated Medical and Behavioral Healthcare Services Billing	15
Tips for billing CPT modifier 33	16
Medical Policy and Clinical Guidelines Updates	16
New Reimbursement Policy - Facility Revenue Code Billing	19
Reimbursement Policy Update - Readmissions (Facility)	19
View reimbursement policies online at anthem.com	19
Genetic testing prior authorization by ordering physician helps ensure accurate lab payment	19
Anthem transitions MA back pain management and cardiology UM programs from OrthoNet to AIM	20
Please evaluate statin use for MA members with diabetes, cardiovascular disease	



October 2018 Anthem Wisconsin Provider Newsletter

.....	20
Medicare pharmacy and prescriber home starts January 2019	21
Keep up with Medicare news	22
Prior authorization requirements for Somatrem	22
Prior authorization requirements for Interferon beta-1a	23
Prior authorization requirements for high-level, definitive drug testing	24
Medical Policies and Clinical Utilization Management Guidelines update - May 2018	25
Medical Policies and Clinical Utilization Management Guidelines update - March 2018	27
Medical Policies and Clinical Utilization Management Guidelines update - January 2018	29
Anthem fights opioid addiction: Extension for Community Health Care Outcomes and Quality Medication-Assisted Therapy	32
Vaginal birth after cesarean shared decision-making aid available	33
EDI Gateway migration	33



Update to AIM Specialty Health clinical appropriateness guidelines

Advanced imaging appropriate use criteria: Imaging of the heart

Effective for dates of service on and after January 28, 2019, the following updates will apply to the AIM Specialty Health© (AIM), a separate company, clinical appropriateness guidelines: advanced imaging appropriate use criteria: imaging of the heart:

Carotid duplex ultrasound

- Criteria removed for evaluation of syncope in patients with suspected extracranial arterial disease
- New criteria address evaluation of TAVR (TAVI) in patients with suspected or established extracranial arterial disease

Myocardial perfusion imaging (MPI), stress echocardiography, cardiac PET, and coronary CT angiography (CCTA)

- Clarifications address exercise-induced syncope and exercise-induced dizziness, lightheadedness or near syncope in symptomatic patients with suspected coronary artery disease

MPI, stress echocardiography, cardiac PET

- Criteria added to allow annual surveillance of coronary artery disease in patients with established CAD post-cardiac transplant
- Clarified definition of established coronary artery disease when diagnosed by CCTA
 - More restrictive for patients diagnosed with coronary artery disease by prior coronary angiography, as FFR must be ≤ 0.8
 - More permissive for patients diagnosed with coronary artery disease by CCTA with FFR ≤ 0.8 (patients previously excluded)

Resting transthoracic echocardiography (TTE)

- New criteria for evaluation of ventricular function in patients who have undergone cardiac transplantation.

Cardiac MRI

- New criteria allows for annual study to quantify cardiac iron load in chronically ill patients with cardiomyopathy who require frequent blood transfusions (e.g., thalassemia)
- Removed allowance for annual LV function evaluation when echocardiography is suboptimal

October 2018 Anthem Wisconsin Provider Newsletter

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's ProviderPortalSM directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at availity.com.
- Call the AIM Contact Center toll-free number: 1-800-554-0580, Monday-Friday, 8:30 a.m.-7:00 p.m. ET.

For questions related to guidelines, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com. Additionally, you may access and download a copy of the current guidelines on [AIM's website](#).

Please note, this program does not apply to FEP.

Update to AIM Specialty Health radiation oncology clinical appropriateness guidelines

Effective for dates of service on and after January 28, 2019, the following updates will apply to the AIM Specialty Health© (AIM), a separate company, radiation oncology clinical appropriateness guidelines.

Breast cancer

- Removed age and tumor size criteria for accelerated whole breast irradiation (AWBI)

Rectal cancer

- Modified criteria no longer limits treatment with IMRT for rectal adenocarcinoma

Pancreatic cancer

- Added criteria for SBRT in treating locally advanced or recurrent disease without evidence of distant metastasis

Head and neck cancer

- Added criteria to allow IMRT for head and neck lymphomas
- Clarified no IMRT for stage I/II glottic cancer

Lung cancer

- Added DVH parameter for cardiac V50

Sarcoma

- Removed preoperative and joint sparing requirements for IMRT

October 2018 Anthem Wisconsin Provider Newsletter

Prostate cancer

- Added discussion on hypofractionation
- Added discussion on brachytherapy

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's ProviderPortalSM directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at availity.com.
- Call the AIM Contact Center toll-free number: 1-800-554-0580, Monday-Friday, 8:30 a.m.-7:00 p.m. ET.

For questions related to guidelines, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com. Additionally, you may access and download a copy of the current guidelines on AIM's [website](#).

Please note, this program does not apply to FEP or National Accounts.

Update to AIM Specialty Health sleep disorder management clinical appropriateness guidelines

Effective for dates of service on and after January 28, 2019, CPT code A7047 (oral interface used with respiratory suction pump) will be removed from the AIM Specialty Health© (AIM), a separate company, sleep disorder management clinical appropriateness guidelines and will no longer apply.

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's ProviderPortalSM directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at availity.com
- Call the AIM Contact Center toll-free number: 1-800-554-0580, Monday-Friday, 8:30 a.m.-7:00 p.m. ET.

For questions related to guidelines, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com. Additionally, you may access and download a copy of the current guidelines on AIM's [website](#).

October 2018 Anthem Wisconsin Provider Newsletter

Please note, this program does not apply to FEP.

Anthem fights opioid addiction: Extension for Community Healthcare Outcomes and Quality Medication-Assisted Therapy

Extension for Community Healthcare Outcomes (ECHO)

Opioid overdose rates continue to rise. With the support of MAT ECHO, you can help save lives. Join one of several video tele-consultative ECHO learning communities nationwide and participate with other clinicians learning about medication-assisted treatment for individuals with opioid disorders. For more information, visit the [ECHO website](#).

Benefits of participating include:

- Addiction treatment training.
- Free continuing education credits.
- Opportunity to receive expert input on your (de-identified) patient cases.
- Access to a virtual learning community for treatment guidelines, tools and patient resources.
- Opportunity to ask questions and get a variety of support from specialists.

Quality Medication-Assisted Therapy (MAT)

To help ensure members have access to comprehensive evidence-based care, Anthem is committed to helping its providers double the number of members who receive behavioral health services as part of MAT for opioid addiction.

When treating patients with opioid use disorder, it is considered best practice to offer and arrange evidence-based treatment. This usually consists of MAT with buprenorphine or, in some plans, methadone maintenance treatment in combination with behavioral therapies. Behavioral therapies focused on medication adherence and relapse prevention can improve MAT outcomes and improve other social determinants of health, including development of an enhanced social support network in recovery.

For more information

For more information about best practices for medication-assisted treatment, please read the American Society of Addiction Medicine's [National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use](#).

You can also contact Jennifer Tripp by email at jennifer.tripp@anthem.com for more information about the ECHO and MAT programs.

October 2018 Anthem Wisconsin Provider Newsletter

Health Care Reform (including Health Insurance Exchange) Updates and Notifications

Please be sure to check the Health Care Reform Updates and Notifications and Health Insurance Exchange sections at anthem.com for new updates on health care reform and Health Insurance Exchanges.

Sign up to receive immediate notification of new information.

Note that in addition to this newsletter and our website, we also use our email communication, *Network eUpdates*, to communicate new information.

If you are not yet signed up to receive *Network eUpdates*, we encourage you to enroll now so you'll be sure to receive all information that we send about Exchanges. Sign up [here](#).

Access patient-specific drug benefit information through EMR

Providers can access real-time, patient-specific prescription drug benefit information at the point of care. It is part of the e-prescribing process, and is located within a provider's electronic medical record (EMR) system.

This functionality helps providers determine prescription coverage quicker by sharing information about patient drug cost, formulary, and coverage alerts such as prior authorization to sending a prescription to the pharmacy. This information can help providers proactively identify barriers to medication compliance. For example, if a medication is too costly for the member, alternatives can be discussed prior to the patient leaving the provider's office.

Providers can find the following patient-specific prescription benefit information with their EMR:

- Formulary status of selected medication
- Pricing of medication at a retail and mail order pharmacy
- Formulary alternatives
- Coverage alerts, including prior authorization and step therapy

Providers should contact their IT department or EMR system with questions regarding access to real-time prescription drug benefit functionality. Upgrades to EMR software may be required.

October 2018 Anthem Wisconsin Provider Newsletter

Anthem expands specialty pharmacy prior authorization list

Effective for dates of service on and after January 1, 2019, the following specialty pharmacy codes from new or current medical policies or clinical UM guidelines will be included in our prior authorization review process.

Please note, inclusion of NDC code on your claim will shorten the claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

Anthem's prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.

The following clinical guidelines or medical policies will be effective January 1, 2019:

Coverage or Clinical UM Guideline	Drug	HCPCS/ CPT Code	NDC Code	Comments
DRUG.00096	Trogarzo™	J3490 J3590	62064-0122-02	New policy

Anthem expands specialty pharmacy level of care (clinical site of care) drug list

Effective for dates of service on and after January 1, 2019, the following specialty pharmacy codes from new or current medical policies or clinical UM guidelines will be included in our existing specialty pharmacy level of care review process.

Anthem's level of care prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.

View the [Level of Care \(Clinical Site of Care\) drug list](#) and [Level of Care \(Clinical Site of Care\) pre-service clinical review FAQs](#) for more information.

Medical Policy or Clinical UM Guideline	Drug	HCPCS/ CPT Code	NDC Code
CG-DRUG-16	Fulphila™	Q5108	67457-0833-06

October 2018 Anthem Wisconsin Provider Newsletter

Anthem expands specialty pharmacy clinically equivalent drug list

Effective for dates of service on and after January 1, 2019, the following specialty pharmacy codes from new or current medical policies or clinical UM guidelines will be included in our existing specialty pharmacy clinically equivalent review process.

Please note, inclusion of NDC code on your claim will shorten the claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

Anthem's clinically equivalent prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.

Medical Policy or Clinical UM Guideline	Drug	HCPCS/ CPT Code	NDC Code
CG-DRUG-16	Fulphila™	Q5108	67457-0833-06

Pharmacy information available at anthem.com

For more information on copayment/coinsurance requirements and their applicable drug classes, drug lists and changes, prior authorization criteria, procedures for generic substitution, therapeutic interchange, step therapy or other management methods subject to prescribing decisions, and any other requirements, restrictions, or limitations that apply to using certain drugs, visit <https://www11.anthem.com/pharmacyinformation/>. The commercial drug list is posted to the website quarterly (the first of the month for January, April, July and October).

FEP Pharmacy updates and other pharmacy related information may be accessed at www.fepblue.org, then Pharmacy Benefits. AllianceRX Walgreens Prime is the specialty pharmacy program for the FEP. You can view the [2018 Specialty Drug List](#) or call us at 888-346-3731 for more information.

Updated Provider Manual posted to anthem.com

Provider Manual Update - Requested Medical Records Submission Functionality


Anthem Blue Cross and Blue Shield (Anthem) recently updated the Claim Inquiry/Adjustment Filing Tips section of our online Provider Manual. The update includes information on functionality to submit medical records requested by Anthem via Availity that was not available when the 2018 Provider Manual was originally posted. More detailed information on this functionality can be found in the [August 2018 Network Update Newsletter](#). The updated

October 2018 Anthem Wisconsin Provider Newsletter

manual is available on our public provider website at anthem.com. Select **Providers** under **Partners in Health**. On the Provider landing page, choose **Find Resources for Your State** and choose **Wisconsin**. On the **Provider home page**, choose **Communications**, then **Publications**.

Anthem launches additional changes to anthem.com in October

Continuing to build on the initial launch of the new public provider pages, Anthem Blue Cross and Blue Shield (Anthem) recently released a brand new, redesigned landing page for Provider Resources. The most recent release also includes a new Communications page with a clear and concise access point for Newsletters and eUpdates, as pictured below.



This October, anthem.com will be introducing exciting changes to the public provider site. Coming in the next wave of changes, providers can anticipate a new landing page for manuals and an improved, streamlined experience for Reimbursement Policies.

October 2018 Anthem Wisconsin Provider Newsletter

We will continue to keep you informed on upcoming changes to the public provider site as we progress toward streamlining our web platform and other business processes.

Availity: Anthem's EDI Gateway is now through Availity

Anthem has partnered with Availity to operate and service the entry point for all EDI submissions to Anthem, otherwise known as the EDI Gateway.

Who is Availity?

Most of you know Availity as web portal or claims clearinghouse, but they are much more. Availity is also an intelligent EDI Gateway for multiple vendors and will be the EDI connection for all Anthem Inc. and its affiliates.

If you currently use a clearinghouse, billing company or if you submit directly, all your EDI transactions will flow through the Availity EDI Gateway to Anthem.

How are you submitting EDI transactions today?

- If you currently transmit your EDI Submissions using a clearinghouse or Billing Company, you should contact your clearinghouse to confirm your EDI submission path has not changed.
- If you are notified of any potential impacts with connectivity, workflow or financial, please know there is no cost alternate submission options available with Availity.
- If you currently submit directly to Anthem and already have an Availity login for the portal, you can use that same login for your EDI services.
- Please visit <https://apps.availity.com/web/welcome/#/anthem> to learn more.

How can you directly transmit EDI submission to Availity?

Below are the different ways you can submit direct EDI transactions to Availity:

- Submit transaction files through FTP - If you work with a practice management system, health information system, or other automated system that supports an FTP connection, you can securely upload EDI transactions to the Availity FTP site where they are automatically picked up by Availity and submitted to Anthem
- Submit transaction files through the Availity Portal - If you have batch files of EDI transactions that you need to process and you choose not to use the Availity FTP site, you can manually upload the batch files through the Availity Portal.
- Submit transactions through manual data entry in the Availity Portal - The Availity Portal makes it easy to submit transactions, such as eligibility and benefits inquiries or

October 2018 Anthem Wisconsin Provider Newsletter

claims, by entering data into our user-friendly web forms.

What are your next steps?

- It may take time to work with your clearinghouse or billing company, so please take action now to help ensure continuity of your EDI transactions.
- If you choose to submit direct, we recommend that you register with Availity for your EDI transmissions and begin migrating your volume by the end of 2018 by visiting this URL- <https://apps.availity.com/web/welcome/#/anthem>
- The EDI transactions include the 837, 835 and 27X (eligibility and claim status).
- Availity will be working directly with your Clearinghouse, Billing Companies or your organization if you choose to submit directly.

We look forward to delivering a smooth transition to the Availity EDI Gateway. If you have any questions please contact Availity Client Services at 1-800-Availity (1-800-282-4548) Monday through Friday 8:00 a.m. to 7:30 p.m. Eastern Time.

Availity EDI Gateway Webinars Scheduled

Great news! Anthem, Inc. and our affiliates now use Availity as our designated EDI service. If you currently use a clearinghouse, billing company, or if you submit directly, all your EDI transactions will flow through the Availity EDI Gateway to Anthem.

Check out this webinar for lots of great information to get you started. At the end of the training, you can participate in a live Q&A session. During this fast paced hour, learn how to:

- Understand Availity's EDI Gateway and Clearinghouse workflow for 837, 270/271, 276/277, and 835 transactions.
- Use the Availity Portal to manage file transfers, set up EDI reporting preferences, manage your FTP account, and more.
- Enroll for and manage 835 ERA delivery with Availity.
- Access and navigate the Availity EDI Guide.
- and more....

Upcoming Sessions

Currently scheduled upcoming sessions include:

- October 29, 2018, 1:00 p.m. – 2:00 p.m. ET
- November 7, 2018, 11:00 a.m. – 12:00 p.m. ET

Enroll

October 2018 Anthem Wisconsin Provider Newsletter

1. Log in to the Availity Portal.
2. Select Help and Training > Get Trained.
3. In the Availity Learning Center (ALC) Catalog, select Sessions.
4. Scroll Your Calendar to find and enroll for a live session.

Can't make it?

We've got you covered with a recording of a previous live session. In the ALC, search the Catalog by keyword (song) and enroll for the on-demand option.

Need Help?

Email training@availity.com if you have issues enrolling for a live webinar.

Explore new enhancements to the Availity Education and Reference Center

The Availity Education and Reference Center (ERC) offers the Communication & Education section where you can find training materials, important policy information, commonly used forms and reference guides on Anthem's proprietary tools. When you visit the ERC, you can efficiently navigate to all available electronic resources using only the Availity Portal.

The Communication and Education section includes two new categories to help make it easier for you to find what you need: Payer Spaces and Interactive Care Reviewer.

With an Availity log in you can easily view any new content added to the ERC. There is no additional role assignment needed.

Find the ERC on the Availity Portal under Payer Spaces / Anthem / Applications. If you are having trouble locating the Education and Reference Center, type Education and Reference Center in the Availity Search option located on the top navigation menu. Select the heart next to the application to save it to your Favorites.

Special Investigations Unit (SIU) Updates: FDA Warnings

The Special Investigations Unit (SIU) is tasked to conduct investigations involving allegations of fraud, waste and abuse, to work with our providers to resolve billing practice issues in order to reduce or eliminate future payment issues, and, where appropriate, to recover overpayments.

October 2018 Anthem Wisconsin Provider Newsletter

As part of Anthem's role to safeguard our members and provide relevant information to providers we are relaying the following recent Food and Drug Administration (FDA) Warning Letters:

Estring - On June 19, 2018 the Food and Drug Administration issued a letter of warning to Pfizer for "false or misleading" promotional materials related to ESTRING® (estradiol vaginal ring). According to the FDA the posted "... video is especially concerning from a public health perspective because it fails to include **any** risk information about Estring, which is a drug that bears a boxed warning due to several serious, life-threatening risks, including endometrial cancer, breast cancer, and cardiovascular disorders, as well as numerous contraindications and warnings. The video thus creates a misleading impression about the safety and efficacy of Estring".

Xtampza ER --On February 9, 2018 the Food and Drug Administration issued a letter of warning to Collegium Pharmaceuticals for publicly providing false or misleading representations regarding Xtampza (oxycodone) ER because it "fails to adequately communicate information about the serious risks associated with Xtampza ER use".

Further details regarding these Warning Letters from the FDA can be obtained from the [FDA website](#):

- [Information about Estring](#)
- [Information about Xtampza ER](#)

HEDIS® 2018: Provider Incentive Winners Announced!

We have completed the HEDIS data collection for 2018 and want to thank all of our provider offices and their staff who assisted us. Your collaboration in this process allows us to strive for the best HEDIS results possible.

This is the seventh year for our incentive program to acknowledge some of our providers who either responded in a timely manner or went "Above and Beyond" to help make our HEDIS data collection successful. Any practices that responded within five business days of our initial request or who went out of their way by taking additional steps to help us with data collection were entered in a drawing to receive a gift. We are pleased to announce that our incentive winners are as follows:

HEDIS Drawing Winners

- Borkowf and Borkovec MD SC dba Watertown OB/GYN

October 2018 Anthem Wisconsin Provider Newsletter

- Gerald L. Ignace Indian Health Center Inc.
- Monroe Clinic
- Prohealth
- Unitypoint Health

Above and Beyond Winners

- Holy Family Memorial Hospital/HFM Family Medicine
- Marshfield/Lakeview Clinics
- Thedacare

Our HEDIS results reflect the care you provide to our members. Now is the time to review your patient's records to ensure that they have received their preventative care and/or immunizations before the end of the year.

An overview of our HEDIS rates will be published in the 4th quarter provider newsletter. In addition more information on HEDIS can be found by visiting the provider portal at: www.anthem.com and select *Provider*, then *Wisconsin*, then *Health & Wellness*, then *Quality Improvement and Standards*, then *HEDIS Information*.

Thanks again to all of our provider offices and their staff for assisting us in collecting HEDIS data. We look forward to working with you next HEDIS season!

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

Are you looking for innovative ways to improve your patients' experiences and earn CME credits?

Numerous studies have shown that a patient's primary health care experience and, to some extent their health care outcomes, are largely dependent upon health care provider and patient interactions. Anthem Blue Cross and Blue Shield (Anthem) offers a new online learning course, *What Matters Most: Improving the Patient Experience*, to address gaps in and offer approaches to communication with patients. This curriculum is available at no cost to providers and their clinical staff nationwide and is acceptable for up to one (1) prescribed credit by the American Academy of Family Physicians.

Through the use of compelling real-life stories that convey practical strategies for implementing patient care, providers learn how to apply best practices.

Did you know?

October 2018 Anthem Wisconsin Provider Newsletter

- Substantial evidence points to a positive association between the patient experience and health outcomes.
- Patients with chronic conditions, such as Diabetes, demonstrate greater self-management skills and quality of life when they report positive interactions with their health care providers.
- Patients reporting the poorest-quality relationships with their physicians were three times more likely to voluntarily leave the physician's practice than patients with the highest-quality relationships.

How will this benefit you and your office staff? You'll learn tips and techniques to:

- Improve communication skills.
- Build patient trust and commitment.
- Expand your knowledge of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey.

The course can be accessed at **www.patientexptraining.com** using your smartphone, tablet, or computer.

Like you, Anthem is committed to improving the patient experience in all interactions, and we are proud to work collaboratively with our provider network to provide support and tools to reach our goal.

Take the course today!

Update to Durable Medical Equipment - effective October 14, 2018

Effective October 14, 2018, Anthem BCBS will enforce the requirement to bill the correct modifier and HCPCS for services utilized. Incorrect billing will be rejected and claims will be returned to the provider for correction and resubmittal.

Durable Medical Equipment (DME) may be purchased, rented or rented until the purchase price has been paid.

Correct billing will allow member benefits to be applied correctly to include benefit accumulations for a member's DME benefits.

October 2018 Anthem Wisconsin Provider Newsletter

Clinical practice and preventive health guidelines

As part of our commitment to provide you with the latest clinical information and educational materials, we have adopted nationally recognized medical, behavioral health, and preventive health guidelines, which are available on anthem.com. The guidelines, which are used for our Quality programs, are based on reasonable medical evidence, and are reviewed for content accuracy, current primary sources, the newest technological advances and recent medical research. All guidelines are reviewed annually, and updated as needed. The current guidelines are available on our website. To access the guidelines, select your state: [Indiana](#), [Kentucky](#), [Missouri](#), [Ohio](#), [Wisconsin](#).

Integrated Medical and Behavioral Healthcare Services Billing

In our ongoing efforts to encourage medical and behavioral health integration, Anthem continues to promote early identification and intervention of behavioral health issues through primary care.

Anthem currently reimburses for screening and assessment for behavioral health and substance use through billing the following codes:

- G0396 /99408 - Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST), and brief intervention 15 to 30 minutes
- G0397 / 99409 - Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST), and brief intervention, greater than 30 minutes
- G0442 - Annual alcohol misuse screening, 15 minutes £ G0443 - Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes
- G0443 - Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes
- G0444 - Annual depression screening, 15 minutes

Anthem also supports behavioral counseling for specific chronic conditions while in the primary care office. These services include:

- G0446 - Annual, face-to-face intensive behavioral therapy for cardiovascular disease, 15 minutes
- G0447 - Face-to-face behavioral counseling for obesity, 15 minutes
- G0473 - Face-to-face behavioral counseling for obesity, group (2-10), 30 minutes

In addition, Anthem reimburses for the psychiatric collaborative care codes; procedure codes 99492, 99493, 99494 are used to report these services. These codes are reportable by primary care for their collaboration with a qualified behavioral health provider, such as a Psychiatrist, Licensed Clinical Social Worker, etc. Care is directed by the primary care team

October 2018 Anthem Wisconsin Provider Newsletter

and includes structured care management with regular assessments of clinical status using validated tools and modification of treatment as appropriate. The psychiatric consultant provides regular consultations to the primary care team to review the clinical status and care of patients and to make recommendations. These codes are intended to represent the care and management for patients with behavioral health conditions that often require extensive discussion, information-sharing, and planning between a primary care physician and a BH specialist. The American Psychiatric Association (APA) has created a training program for primary care on the collaborative care model and the use of these codes. It can be found at [APA Training Module](#).

Tips for billing CPT modifier 33

The modifier 33 was created to aid compliance with the Affordable Care Act (ACA) which prohibits member cost sharing for defined preventive services for non-grandfathered policies. The appropriate use of modifier 33 will reduce claim adjustments related to preventive services and your corresponding refunds to members.

Modifier 33 is applicable to CPT codes representing preventive care services. CPT codes not appended with modifier 33 will process under the member's medical or preventive benefits, based on the diagnosis and CPT codes submitted.

Modifier 33 should be appended to codes represented for services described in the US Preventive Services Task Force (USPSTF) A and B recommendations, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), and certain guidelines for infants, children, adolescents, and women supported by the Health Resources and Services Administration (HRSA) Guidelines.

The CPT® 2018 Professional Edition manual shares the following information regarding the billing of modifier 33, "When the primary purpose of the service is the delivery of an evidence based service in accordance with a US Preventive Services Task Force A or B rating in effect and other preventive services identified in preventive mandates (legislative or regulatory), the service may be identified by adding 33 to the procedure. For separately reported services specifically identified as preventive, the modifier should not be used."

Medical Policy and Clinical Guidelines Updates

The following new and revised medical policies were endorsed at the July 26, 2018 Medical Policy & Technology Assessment Committee (MPTAC) meeting. These, and all Anthem

October 2018 Anthem Wisconsin Provider Newsletter

medical policies, are available at anthem.com/providers, then scroll down and select "Find Resources for Ohio", then from the Wisconsin Provider Home Page, select [Medical Policies and Clinical UM Guidelines](#).

These medical policies were converted to clinical guidelines and became effective on September 20, 2018.

New Clinical Guideline	Content Moved From Clinical Guideline and/or Medical Policy
CG-DME-45 Ultrasound Bone Growth Stimulation	Content moved from DME.00027 No change to position statement → clinical indications
CG-MED-73 Hyperbaric Oxygen Therapy (Systemic/Topical)	Content moved from MED.00005 No change to position statement → clinical indications
CG-MED-74 Implantable Ambulatory Event Monitors and Mobile Cardiac Telemetry	Content moved from MED.00051 No change to position statement → clinical indications
CG-MED-75 Medical and Other Non-Behavioral Health Related Treatments for Autism Spectrum Disorders and Rett Syndrome	Content moved from MED.00107 No change to position statement → clinical indications
CG-MED-76 Magnetic Source Imaging and Magnetoencephalography	Content moved from RAD.00019 No change to position statement → clinical indications
CG-MED-77 SPECT/CT Fusion Imaging	Content moved from RAD.00042 No change to position statement → clinical indications
CG-REHAB-11 Cognitive Rehabilitation	Content moved from MED.00081 Removed "Note" in Clinical Indications referring to CG-REHAB-09 Acute Inpatient Rehabilitation
CG-SURG-81 Cochlear Implants and Auditory Brainstem Implants	Content moved from SURG.00014 No change to position statement → clinical indications
CG-SURG-82 Bone-Anchored and Bone Conduction Hearing Aids	Content moved from SURG.00020 No change to position statement → clinical indications
CG-SURG-84 Mandibular/Maxillary (Orthognathic) Surgery	Content moved from SURG.00049 No change to position statement → clinical indications
CG-SURG-87 Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring	Content moved from SURG.00074 Revised title - Previous title: Nasal Surgery for the Treatment of Obstructive Sleep Apnea (OSA) and Snoring No change to position statement → clinical indications
CG-SURG-88 Mastectomy for Gynecomastia	Content moved from SURG.00085 No change to position statement → clinical indications
CG-SURG-89 Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia	Content moved from SURG.00090 No change to position statement → clinical indications

October 2018 Anthem Wisconsin Provider Newsletter

CG-TRANS-03 Donor Lymphocyte Infusion for Hematologic Malignancies after Allogeneic Hematopoietic Progenitor Cell Transplantation	Content moved from TRANS.00018 No change to position statement → clinical indications
---	--

These medical policies were converted to clinical guidelines and will become effective on October 31, 2018

New Clinical Guideline	Content Moved From Clinical Guideline and/or Medical Policy
CG-SURG-83 Bariatric Surgery and Other Treatments for Clinically Severe Obesity	Content moved from SURG.00024 No change to position statement → clinical indications
CG-SURG-85 Hip Resurfacing	Content moved from SURG.00051 No change to position statement → clinical indications
CG-SURG-86 Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection	Content moved from SURG.00054 No change to position statement → clinical indications

This new medical policy will be implemented on January 1, 2019

New Medical Policy	Content
GENE.00049 Circulating Tumor DNA Testing for Cancer (Liquid Biopsy)	MPTAC approved this new medical policy which reflects the following: The use of a circulating tumor DNA (ctDNA) test for the diagnosis or treatment of cancer is considered investigational and not medically necessary (INV&NMN) for all indications

This medical policy has been revised and will be effective January 1, 2019

New Medical Policy	Content
ANC.00007 Cosmetic and Reconstructive Services: Skin Related	MPTAC approved revision of policy which reflects the following: • Added microneedling (also known as percutaneous collagen induction therapy or skin needling) as COS&NMN for all indications

This medical policy is archived effective September 1, 2018

GENE.00008 - Analysis of Fecal DNA for Colorectal Cancer Screening and Surveillance

October 2018 Anthem Wisconsin Provider Newsletter

New Reimbursement Policy - Facility Revenue Code Billing

Beginning with dates of service on or after January 1, 2019, Anthem Blue Cross and Blue Shield (Anthem) will require that facilities billing outpatient services on a UB04 report current and valid CPT or HCPCS codes with revenue codes as specified by the National Uniform Billing Committee (NUBC). Anthem will also require that outpatient facilities report current and valid CPT or HCPCS codes for remaining revenue codes when, and if, appropriate CPT or HCPCS codes are available for the revenue codes being reported. In addition, Anthem will require that applicable CPT or HCPCS modifiers be reported with the CPT or HCPCS codes to clarify or improve the accuracy of the procedure being reported when appropriate. For more information about this new policy, visit the [Wisconsin facility reimbursement policy](#) page at anthem.com/provider.

Reimbursement Policy Update - Readmissions (Facility)

Beginning with dates of service on or after January 1, 2019, Anthem Blue Cross and Blue Shield (Anthem) will include readmissions for psychiatric diagnoses as readmissions that are not be eligible for reimbursement when the readmission is within 30 days from discharge of the original admission for the same, similar or related diagnosis or for a complication arising out of the first admission. For more information, review the policy dated January 1, 2019 by visiting the [Wisconsin facility reimbursement policy](#) page at anthem.com/provider.

View reimbursement policies online at anthem.com

To find Anthem's professional and facility reimbursement policies online, select your state: [Indiana](#), [Kentucky](#), [Missouri](#), [Ohio](#), [Wisconsin](#).

Genetic testing prior authorization by ordering physician helps ensure accurate lab payment

The AIM Genetic Testing program requires ordering providers to request medical necessity review of all genetic testing services for individual Medicare Advantage members. Requesting this prior authorization will help ensure that the lab receives timely and accurate payment for these services.

Please submit genetic testing prior authorization requests to AIM through one of the following ways:

October 2018 Anthem Wisconsin Provider Newsletter

- Access AIM ProviderPortalSM directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at availity.com
- Call the AIM Contact Center toll-free number at 800-714-0040, Monday-Friday, 7 a.m.-7p.m. CT.

For further questions regarding prior authorization requirements, please contact the Provider Services number on the back of your patient's ID card.

Anthem transitions MA back pain management and cardiology UM programs from OrthoNet to AIM

Effective January 1, 2019, Anthem will transition its Medicare back pain management and cardiology programs from OrthoNet LLC to AIM Specialty Health® (AIM), a specialty health benefits company. Anthem has an existing relationship with AIM in the administration of other medical management programs. Additional information will be available at Important Medicare Advantage Updates at anthem.com/medicareprovider.

Please evaluate statin use for MA members with diabetes, cardiovascular disease

The Centers for Medicare & Medicaid Services has increased its emphasis on the appropriate use of statins among Medicare Advantage beneficiaries diagnosed with diabetes and cardiovascular disease. Please evaluate whether your patients with diabetes and/or cardiovascular disease would be appropriate candidates for statin therapy.

The 2013 American College of Cardiology and the American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults supports the use of moderate-intensity statin therapy in persons with diabetes 40 to 75 years of age to reduce the risks of atherosclerotic cardiovascular disease (ASCVD) events. High-intensity statin therapy is recommended if the patient has an estimated 10-year ASCVD risk greater than or equal to 7.5 percent. For males 21-75 and females 40-75 years of age with clinical ASCVD, high-intensity statin therapy is recommended unless contraindicated. These guidelines recommend statin therapy in these scenarios regardless of what patient LDL values are. Please evaluate if your patients with diabetes and/or cardiovascular disease would be appropriate candidates for statin therapy.

October 2018 Anthem Wisconsin Provider Newsletter

Formulary agents are listed below:

Moderate-intensity statin therapy (formulary agents)

Drug (brand)	Dose
atorvastatin**	10 mg, 20 mg
rosuvastatin*	5 mg, 10 mg
simvastatin**	20 mg, 30 mg, 40 mg
pravastatin**	40 mg, 80 mg
lovastatin**	40 mg

High-intensity statin therapy (formulary agents)

Drug (brand)	Dose
atorvastatin**	40 mg, 80 mg
rosuvastatin*	20 mg, 40 mg

*Rosuvastatin (Crestor) is a preferred brand medication on the Medicare formulary.

**Available for a \$0 co-pay for most plans in 2018

Medicare pharmacy and prescriber home starts January 2019

Per guidance established by the Comprehensive Addiction and Recovery Act of 2016, the Centers for Medicare & Medicaid Services has established provisions to develop a pharmacy and prescriber home program for opioid medications.

Beginning January 1, 2019, Anthem will work with beneficiaries and providers to help to reduce the risk of opioid dependency by streamlining access to opioid medications. If a beneficiary is exhibiting at-risk opioid medication utilization, the plan sponsor will work with the beneficiary and provider to select a pharmacy home and prescriber home for the beneficiary's opioid medications.

At risk is defined by CMS as:

1. Greater than 90 mg per day cumulative morphine milligram equivalent (MME)
2. Greater than three (3) opioid prescribers and greater than three (3) opioid dispensing pharmacies, or
3. Greater than five (5) opioid prescribers, regardless of the number of pharmacies

Please note:

October 2018 Anthem Wisconsin Provider Newsletter

- Cancer, LTC and Hospice are exempt
- Beneficiaries will have the choice of which pharmacy or prescriber to select as their home.
- Plan sponsors will request agreement from the provider selected as the home.
- At this time, only opioid and benzodiazepine medications will be delegated to a home pharmacy or prescriber.
- Both beneficiaries and providers will receive letters to explain what is happening and how it will happen.
- Beneficiaries retain the right to request a coverage determination and may choose to change their Home pharmacy or prescriber at any time.

Keep up with Medicare news

Please continue to check [Important Medicare Advantage Updates](#) at anthem.com/medicareprovider for the latest Medicare Advantage information, including:

- [Prior authorization requirements for Part B drugs: Moxetumomab Pasudotox, Cemiplimab and Fulphila](#)
- [July Medicare Advantage reimbursement policy](#)
- [Submit PA medication requests electronically; new phone number for MA prescription PAs](#)
- [CMS issues regulatory changes for short- and long-acting narcotics; days' supply limits effective Jan. 1, 2019](#)
- [Inpatient Readmissions](#)
- [CMS issues regulatory changes for short- and long-acting narcotics; days' supply limits effective Jan. 1, 2019](#)
- [Submit PA medication requests electronically; new phone number for MA prescription prior authorizations effective Sept. 1, 2018](#)
- [Expanded membership now available for prior authorization via ICR](#)

Prior authorization requirements for Somatrem

Effective December 1, 2018, prior authorization (PA) requirements will change for injectable/infusible drug Somatrem to be covered by Anthem Blue Cross and Blue Shield. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining

October 2018 Anthem Wisconsin Provider Newsletter

coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- Somatrem — injection, 1 mg (J2940)

To request PA, you may use one of the following methods:

- Web: <https://www.availity.com>
- Fax: 1-800-964-3627
- Phone: 1-855-558-1443

Not all PA requirements are listed here. PA requirements are available to contracted providers through the Availity Portal (<https://www.availity.com>). Providers who are unable to access Availity may call us at 1-855-558-1443 for PA requirements.

Prior authorization requirements for Interferon beta-1a

Effective December 1, 2018, prior authorization (PA) requirements will change for injectable/infusible drug Interferon beta-1a to be covered by Anthem Blue Cross and Blue Shield. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- Interferon beta-1a — injection, 30 mcg (J1826)

To request PA, you may use one of the following methods:

- Web: <https://www.availity.com>
- Fax: 1-800-964-3627
- Phone: 1-855-558-1443

Not all PA requirements are listed here. PA requirements are available to contracted providers through the Availity Portal (<https://www.availity.com>). Providers who are unable to access Availity may call us at **1-855-558-1443** for PA requirements.

Prior authorization requirements for high-level, definitive drug testing

Effective December 1, 2018, prior authorization (PA) requirements will change for high-level, definitive drug testing(s). The high-level, definitive drug testing(s) will require PA for Anthem Blue Cross and Blue Shield members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- G0482 — Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, gas chromatography/mass spectrometry (GC/MS) (any type, single or tandem) and liquid chromatography/mass spectrometry (LC/MS) (any type, single or tandem and excluding immunoassays; e.g., immunoassays [IA]; enzyme immunoassay [EIA]; enzyme-linked immunosorbent assay [ELISA]; enzyme multiplied immunoassay technique [EMIT]; fluorescence polarization immunoassay [FPIA]; and enzymatic methods [e.g., alcohol dehydrogenase]); (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength); and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es) including metabolite(s) if performed.
- G0483 — Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays; e.g., IA; EIA; ELISA; EMIT; FPIA; and enzymatic methods [e.g., alcohol dehydrogenase]); (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength); and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es) including metabolite(s) if performed.

To request PA, you may use one of the following methods:

- Web: <https://www.availity.com>
- Fax: 1-800-964-3627

October 2018 Anthem Wisconsin Provider Newsletter

- Phone: 1-855-558-1443

Not all PA requirements are listed here. PA requirements are available on the provider website at <https://mediproviders.anthem.com/wi> > Precertification. Contracted and non-contracted providers may call Provider Services at **1-855-558-1443** for assistance with PA requirements.

Medical Policies and Clinical Utilization Management Guidelines update - May 2018

The *Medical Policies* and *Clinical Utilization Management (UM) Guidelines* below were developed or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. For markets with carved-out pharmacy services, the applicable listings below are informational only.

Note:

- Effective November 1, 2018, MCG Health Care Guidelines will be used for reviews, to include the use of customizations to certain guidelines and Behavioral Health Care Guidelines (NEW).
- Effective November 1, 2018, AIM Specialty Health Proton Beam Therapy will be used for clinical reviews.

Please share this notice with other members of your practice and office staff.

To search for specific drug policies or guidelines, visit http://www.anthem.com/cptsearch_shared.html.

Medical Policies updates: May 2018

On May 3, 2018, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Anthem Blue Cross and Blue Shield Medicaid (Anthem).

Publish date	Medical Policy number	Medical Policy title	New or revised
6/6/2018	DRUG.00098	Lutetium Lu 177 dotatate (Lutathera®)	New
6/6/2018	DRUG.00046	Ipilimumab (Yervoy®)	Revised
5/10/2018	DRUG.00047	Brentuximab Vedotin (Adcetris®)	Revised
5/10/2018	DRUG.00053	Carfilzomib (Kyprolis®)	Revised

October 2018 Anthem Wisconsin Provider Newsletter

Publish date	Medical Policy number	Medical Policy title	New or revised
6/6/2018	DRUG.00071	Pembrolizumab (Keytruda®)	Revised
6/6/2018	DRUG.00075	Nivolumab (Opdivo®)	Revised
5/10/2018	DRUG.00076	Blinatumomab (Blinicyto®)	Revised
6/6/2018	DRUG.00111	Monoclonal Antibodies to Interleukin-23	Revised
5/10/2018	SURG.00026	Deep Brain, Cortical and Cerebellar Stimulation	Revised

Clinical UM Guidelines updates: May 2018

On May 3, 2018, the MPTAC approved the following *Clinical UM Guidelines* applicable to Anthem. This list represents the guidelines adopted by the medical operations committee for the Government Business Division on April 19, 2018.

Publish date	Clinical UM Guideline number	Clinical UM Guideline title	New or revised
6/6/2018	CG-LAB-12	Testing for Oral and Esophageal Cancer	New
6/6/2018	CG-MED-71	Wound Care in the Home Setting	New
6/28/2018	CG-DME-44	Electric Tumor Treatment Field (TTF)	New
6/28/2018	CG-DRUG-67	Cetuximab (Erbix®)	New
6/28/2018	CG-DRUG-94	Rituximab (Rituxan®) for Nononcologic Indications	New
6/28/2018	CG-DRUG-95	Belatacept (Nulojix®)	New
6/28/2018	CG-DRUG-96	Ado-trastuzumab emtansine (Kadcyla®)	New
6/28/2018	CG-DRUG-97	Rilonacept (Arcalyst®)	New
6/28/2018	CG-DRUG-98	Bendamustine Hydrochloride	New
6/28/2018	CG-DRUG-99	Elotuzumab (Empliciti™)	New
6/28/2018	CG-DRUG-100	Interferon gamma-1b (Actimmune®)	New
6/28/2018	CG-DRUG-101	Ixabepilone (Ixempra®)	New
6/28/2018	CG-DRUG-102	Olaratumab (Lartruvo™)	New
6/28/2018	CG-MED-72	Hyperthermia for Cancer Therapy	New
6/28/2018	CG-SURG-76	Carotid, Vertebral and Intracranial Artery Stent Placement with or without Angioplasty	New
6/28/2018	CG-SURG-77	Refractive Surgery	New
6/28/2018	CG-SURG-78	Locally Ablative Techniques for Treating Primary and Metastatic Liver Malignancies	New
6/28/2018	CG-SURG-79	Implantable Infusion Pumps	New
6/28/2018	CG-SURG-80	Transcatheter Arterial Chemoembolization and Transcatheter Arterial Embolization for Treating Primary or Metastatic Liver Tumors	New

October 2018 Anthem Wisconsin Provider Newsletter

Publish date	Clinical UM Guideline number	Clinical UM Guideline title	New or revised
5/10/2018	CG-DRUG-50	Paclitaxel, protein bound (Abraxane®)	Revised
6/6/2018	CG-DRUG-60	Gonadotropin Releasing Hormone Analogs for the Treatment of Oncologic Indications	Revised
6/6/2018	CG-DRUG-62	Fulvestrant (FASLODEX®)	Revised
6/6/2018	CG-DRUG-78	Antihemophilic Factors and Clotting Factors	Revised

Medical Policies and Clinical Utilization Management Guidelines update - March 2018

The *Medical Policies* and *Clinical Utilization Management (UM) Guidelines* below were developed or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. For markets with carved-out pharmacy services, the applicable listings below are informational only.

Please share this notice with other members of your practice and office staff.

To search for specific policies or guidelines, visit http://www.anthem.com/cptsearch_shared.html.

Medical Policies updates: March 2018

On March 22, 2018, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Anthem Blue Cross and Blue Shield (Anthem).

Publish date	Medical Policy number	Medical Policy title	New or revised
3/29/2018	MED.00120	Voretigene neparvovec-rzyl (Luxturna™)	New
4/25/2018	SURG.00151	Balloon Dilation of Eustachian Tube	New
4/25/2018	DME.00009	Vacuum-Assisted Wound Therapy in the Outpatient Setting	Revised
3/29/2018	GENE.00028	Genetic Testing for Colorectal Cancer Susceptibility	Revised
4/25/2018	RAD.00029	CT Colonography (Virtual Colonoscopy) for Colorectal Cancer	Revised
4/25/2018	SURG.00033	Cardioverter Defibrillators	Revised
4/25/2018	SURG.00098	Mechanical Embolectomy for Treatment of Acute Stroke	Revised

October 2018 Anthem Wisconsin Provider Newsletter

Publish date	Medical Policy number	Medical Policy title	New or revised
4/25/2018	SURG.00121	Transcatheter Heart Valve Procedures	Revised

Clinical UM Guidelines updates: March 2018

On March 22, 2018, the MPTAC approved the following *Clinical UM Guidelines* applicable to Anthem. This list represents the guidelines adopted by the medical operations committee for the Government Business Division on April 19, 2018.

Publish date	Medical Policy number	Medical Policy title	New or revised
6/28/2018	CG-BEH-15	Activity Therapy for Autism Spectrum Disorders and Rett Syndrome	New
6/22/2018	CG-DRUG-89	Implantable and Extended-Release Buprenorphine-Containing Products	New
6/28/2018	CG-DRUG-90	Intravitreal Treatment for Retinal Vascular Conditions	New
6/28/2018	CG-DRUG-91	Intravitreal Corticosteroid Implants	New
6/28/2018	CG-DRUG-92	Alpha-1 Proteinase Inhibitor Therapy	New
6/28/2018	CG-DRUG-93	Sarilumab (Kevzara®)	New
6/28/2018	CG-LAB-13	Skin Nerve Fiber Density Testing	New
6/28/2018	CG-MED-69	Inhaled Nitric Oxide	New
6/28/2018	CG-MED-70	Wireless Capsule Endoscopy for Gastrointestinal Imaging and the Patency Capsule	New
6/28/2018	CG-SURG-73	Balloon Sinus Ostial Dilation	New
6/28/2018	CG-SURG-74	Total Ankle Replacement	New
6/28/2018	CG-SURG-75	Transanal Endoscopic Microsurgical Excision of Rectal Lesions	New
6/28/2018	CG-THER-RAD-07	Intravascular Brachytherapy (Coronary and Noncoronary)	New
4/25/2018	CG-SURG-31	Treatment of Keloids and Scar Revision	Revised
4/25/2018	CG-SURG-49	Endovascular Techniques (Percutaneous or Open Exposure) for Arterial Revascularization of the Lower Extremities	Revised

October 2018 Anthem Wisconsin Provider Newsletter

Medical Policies and Clinical Utilization Management Guidelines update - January 2018

Medical Policies update: January 2018

On January 25, 2018, the medical policy and technology assessment committee (MPTAC) approved the following *Medical Policies* applicable to Anthem Blue Cross and Blue Shield Medicaid (Anthem). These policies were developed or revised to support clinical coding edits. Several policies were revised to provide clarification only and are not included in the below listing.

The *Medical Policies* were made publicly available on our provider website on the effective date listed. To search for specific policies, visit http://www.anthem.com/cptsearch_shared.html.

Please note:

- Starting July 1, 2018, AIM Specialty Health® *Cardiology and Radiation Oncology Guidelines* are utilized for clinical reviews.
- For markets with carved-out pharmacy services, the applicable listings below are informational only.

Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff.

Publish date	Medical Policy number	Medical Policy title	New or revised
2/28/2018	DRUG.00116	Vestronidase alfa (Mepsevii™)	New
2/28/2018	DRUG.00046	Ipilimumab (Yervoy®)	Revised
2/28/2018	DRUG.00075	Nivolumab (Opdivo®)	Revised
2/28/2018	DRUG.00077	Monoclonal Antibodies to Interleukin-17A	Revised
2/1/2018	DRUG.00080	Monoclonal Antibodies for the Treatment of Eosinophilic Conditions	Revised
2/28/2018	DRUG.00082	Daratumumab (DARZALEX™)	Revised
2/28/2018	DRUG.00099	Cerliponase Alfa (Brineura™)	Revised
2/28/2018	GENE.00028	Genetic Testing for Colorectal Cancer Susceptibility	Revised
2/1/2018	GENE.00029	Genetic Testing for Breast and/or Ovarian Cancer Syndrome	Revised
2/28/2018	GENE.00035	Genetic Testing for TP53 Mutations	Revised

October 2018 Anthem Wisconsin Provider Newsletter

Publish date	Medical Policy number	Medical Policy title	New or revised
2/28/2018	MED.00100	Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing Systems	Revised
2/1/2018	SURG.00011	Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft Tissue Grafting	Revised
2/1/2018	SURG.00098	Mechanical Embolectomy for Treatment of Acute Stroke	Revised
2/28/2018	SURG.00145	Mechanical Circulatory Assist Devices (Ventricular Assist Devices, Percutaneous Ventricular Assist Devices and Artificial Hearts)	Revised

Clinical Utilization Management Guidelines update: January 2018

On January 25, 2018, the MPTAC approved the following *Clinical Utilization Management (UM) Guidelines* applicable to Anthem. These clinical guidelines were developed or revised to support clinical coding edits. Several guidelines were revised to provide clarification only and are not included in the following listing. This list represents the *Clinical UM Guidelines* adopted by the medical operations committee for the Government Business Division on March 2, 2018.

The clinical guidelines were made publicly available on our provider website on the effective date listed. To search for specific guidelines, visit http://www.anthem.com/cptsearch_shared.html.

Please note:

- Starting July 1, 2018, AIM Specialty Health® *Cardiology and Radiation Oncology Guidelines* are utilized for clinical reviews.
- For markets with carved-out pharmacy services, the applicable listings below are informational only.

Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff.

October 2018 Anthem Wisconsin Provider Newsletter

Publish date	Medical Policy number	Medical Policy title	New or revised
5/1/2018	CG-DME-42	Nonimplantable Insulin Infusion and Blood Glucose Monitoring Devices	New
5/1/2018	CG-DME-43	High-Frequency Chest Compression Devices for Airway Clearance	New
5/1/2018	CG-DRUG-82	Prostacyclin Infusion Therapy and Inhalation Therapy for Treatment of Pulmonary Arterial Hypertension	New
5/1/2018	CG-DRUG-83	Growth Hormone	New
5/1/2018	CG-DRUG-84	Belimumab (Benlysta®)	New
5/1/2018	CG-DRUG-85	Tesamorelin (Egrifta®)	New
5/1/2018	CG-DRUG-86	Ocriplasmin (Jetrea®) Intravitreal Injection Treatment	New
5/1/2018	CG-DRUG-87	Vedolizumab (Entyvio®)	New
5/1/2018	CG-DRUG-88	Dupilumab (Dupixent®)	New
5/1/2018	CG-SURG-70	Gastric Electrical Stimulation	New
5/1/2018	CG-SURG-71	Reduction Mammoplasty	New
5/1/2018	CG-SURG-72	Endothelial Keratoplasty	New
7/1/2018	CG-THER-RAD-03	Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy	New
7/1/2018	CG-THER-RAD-04	Selective Internal Radiation Therapy of Primary or Metastatic Liver Tumors	New
5/1/2018	CG-DRUG-29	Hyaluronan Injections	Revised
2/28/2018	CG-DRUG-50	Paclitaxel, protein bound (Abraxane®)	Revised
2/28/2018	CG-DRUG-59	Testosterone Injectable	Revised
2/28/2018	CG-DRUG-73	Denosumab (Prolia®, Xgeva®)	Revised
2/28/2018	CG-DRUG-78	Antihemophilic Factors and Clotting Factors	Revised
2/28/2018	CG-MED-39	Central (Hip or Spine) Bone Density Measurement and Screening for Vertebral Fractures Using Dual Energy X-Ray Absorptiometry	Revised
2/28/2018	CG-MED-53	Cervical Cancer Screening Using Cytology and Human Papillomavirus Testing	Revised

October 2018 Anthem Wisconsin Provider Newsletter

Publish date	Medical Policy number	Medical Policy title	New or revised
2/28/2018	CG-SURG-33	Lumbar Fusion and Lumbar Total Disc Arthroplasty	Revised

Anthem fights opioid addiction: Extension for Community Health Care Outcomes and Quality Medication-Assisted Therapy

Extension for Community Health Care Outcomes (ECHO)

Opioid overdose rates continue to rise. With the medication assisted treatment, you can help save lives! Join one of several video tele-consultative ECHO learning communities nationwide and participate with other clinicians learning about medication-assisted treatment for individuals with opioid disorders. For more information, visit the ECHO website at <https://echo.unm.edu>.

Benefits of participating include:

- Addiction treatment training.
- Free continuing education credits.
- Opportunity to receive expert input on your (de-identified) patient cases.
- Access to a virtual learning community for treatment guidelines, tools and patient resources.
- Opportunity to ask questions and get a variety of support from specialists.

Quality Medication-Assisted Therapy (MAT)

To help ensure members have access to comprehensive evidence-based care, Anthem is committed to helping its providers double the number of members who receive behavioral health services as part of MAT for opioid addiction.

When treating patients with opioid use disorder, it is considered best practice to offer and arrange evidence-based treatment. This usually consists of MAT with naltrexone, buprenorphine or, in some plans, methadone in combination with behavioral therapies. Behavioral therapies focused on medication adherence and relapse prevention can improve MAT outcomes and improve other social determinants of health, including development of an enhanced social support network in recovery.

For more information

For more information about what is considered best practice for medication-assisted treatment, please read the American Society of Addiction Medicine's [National Practice](#)

October 2018 Anthem Wisconsin Provider Newsletter

[Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.](#)

You can also contact Jennifer Tripp by email at jennifer.tripp@anthem.com for more information about the ECHO and MAT programs.

Vaginal birth after cesarean shared decision-making aid available

As part of our commitment to provide you with the latest clinical information and improve member outcomes, we have posted a vaginal birth after cesarean (VBAC) shared decision-making aid to our provider site. This tool has been reviewed and certified by the Washington Health Care Authority* and is available to aid in discussions with your patients regarding their treatment options.

If you have questions about this communication or need assistance with any other item, contact your local Provider Relations representative or call Provider Services at **1-855-661-2028**.

* The Washington Health Care Authority is recognized as a certifying body by NCQA.

EDI Gateway migration

Anthem Blue Cross and Blue Shield has partnered with Availity to become our designated EDI Gateway, effective January 1, 2019.

What does this mean to you as a provider?

All EDI submissions currently received are now available on Availity. Please note, there is no impact to provider participation statuses and no impact on how claims adjudicate.

Next steps

Contact your clearinghouse to validate their transition dates to Availity. If your clearinghouse notifies you of changes regarding connectivity, workflow or the financial cost of EDI transactions, there is a no-cost option available to you. You can submit claims directly through Availity!

Register with Availity

If you wish to submit directly through Availity for your 837 (claim), 835 (electronic remittance advice) and 27X (claim status and eligibility) transactions, please visit <https://www.availity.com> to register.

We look forward to delivering a smooth transition to the Availity EDI Gateway.

October 2018 Anthem Wisconsin Provider Newsletter

If you have any questions please contact Availity Client Services at **1-800-282-4548**, Monday to Friday, 8 a.m. to 7:30 p.m. Eastern time.